Home › Alzheimer's Disease › NCT03503331
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
Who can join
Ages 50 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: \- 1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol (IRB-300000169). 2\. Negative urine or serum B-hCG test within 2 days of \[C-11\]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing. Exclusion Criteria: 1. Meets any exclusion criteria for the UAB-ADC study (IRB-300000169). 2. Inability or contraindication for undergoing MRI and/or PET imaging 3. Inability to participate in the imaging studies due to severity of dementia
About the study
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \[C-11\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \[C-11\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.
What is being tested
- [C-11]PiB-PET/MRI (drug)
Sponsor: University of Alabama at Birmingham · Participants: 160 · Started: Apr 20, 2018
Contact the study team
- Chinara Dosse · Phone: (205) 975-7017
- Evan Hudson · Phone: 205-934-6499
Official record on ClinicalTrials.gov — NCT03503331
Locations in the U.S.
| Alabama | University of Alabama at Birmingham Medical Center, Birmingham |
Conditions
From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.